Of late, SGN‐CD228A, a melanotransferrin mAb conjugated to 8 MMAE molecules (DAR of 8) using glucuronide hydrophilic linker instead of a valine citrulline, recently progressed to a phase‐I clinical trial for the treatment of melanoma, mesothelioma, and TNBC patients expressing melanotransferrin receptor (NCT04042480) [217]. The gene discussed is MELTF; the disease is melanoma.